Medicenna Achieves Landmark Response in Cancer Treatment with MDNA11 and KEYTRUDA®Business PenDecember 5, 2024 December 5, 2024 Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company, recently provided a significant update on its Phase 1/2 ABILITY-1 study, showcasing promising results...
